Premium
The Evolution and Future of CAR T Cells for B‐Cell Acute Lymphoblastic Leukemia
Author(s) -
Annesley Colleen E.,
Summers Corinne,
Ceppi Francesco,
Gardner Rebecca A.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.950
Subject(s) - cytokine release syndrome , cd19 , lymphoblastic leukemia , chimeric antigen receptor , neurotoxicity , medicine , clinical trial , cytokine , immunology , car t cell therapy , t cell , leukemia , acute lymphocytic leukemia , antigen , oncology , cancer research , toxicity , immune system
Several CAR T designs with CD19 specificity have been associated with consistent responses in clinical trials with complete remission (CR) rates ranging from 70–90%. Relevant challenges remain to be addressed, such as production time, early loss of CAR T cells, relapse due to loss of the target antigen, and prevention of severe cytokine release syndrome and neurotoxicity. This review describes constructs, clinical trial results, side effects, and future direction of CAR T‐cell therapy in B‐ALL.